Proteomics
Alternative gene therapies could be effective in treating some rare diseases
Bacteria-mediated genetic transfer has emerged as an alternative gene therapy (AGT) for the treatment of some rare diseases, such as phenylketonuria (PKU). This type of therapy is advantageous because it is easily regulated through established protein expression systems. One company, Synlogic, has developed an AGT candidate that uses a bacterial vector to treat PKU. Read More
Prime editing shows promise for complex diseases like cystic fibrosis
Researchers have demonstrated that prime editing -- a newer version of CRISPR-Cas9 gene editing -- can be successfully employed to correct gene mutations that cause cystic fibrosis. The new study, which tested the technique in human organoids, was published in Life Science Alliance on August 9. Read More
New sequencing workflow efficiently maps protein-protein interactions
A new tool called protein-protein interaction sequencing (PROPER-seq) allows researchers to map complex networks of proteins within cells of interest without the need for specialized resources, like antibodies or premade gene libraries. The methodology was published in Molecular Cell on August 3. Read More
Integral Molecular launches protein engineering platform
Integral Molecular announced the launch of its proprietary protein engineering platform, GeneCanvas, for the optimization of transgenes and other elements that are essential for gene therapy development. Read More
Cardiac cell protein may be key to preventing heart failure
A protein that controls calcium signaling within heart cells could help prevent chronic heart failure, according to the results of a new study published in Nature Communications on July 28. The findings point to the protein as a therapeutic target for drugs that could alleviate heart failure. Read More
Amgen to buy private firm Teneobio for $900M
Amgen will spend $900 million in cash to acquire the privately held biotechnology company Teneobio, which is developing a new class of biologics known as human heavy-chain antibodies. Read More
Blocking some T cells may unleash full power of immune system against cancer
Researchers have identified a way to restrict regulatory T-cell activity in tumor cells, which in turn can unleash other immune cells to attack tumors in cancer patients. The research is being published in the August 3 issue of the Proceedings of the National Academy of Sciences. Read More
Cytiva, Pall to invest $1.5B in biomanufacturing over next 2 years
Cytiva and Pall, both Danaher companies, will make major investments in manufacturing capacity and services at 13 sites around the globe supporting life science customers, totaling $1.5 billion over two years. Read More
EMBL partners with DeepMind to predict 3D structure of human proteins
Google Health's DeepMind announced a partnership with the European Molecular Biology Laboratory (EMBL) to offer the scientific community open access to the most comprehensive database developed to date of predicted 3D protein structures. Read More
Gene therapy tackles 2 rare childhood diseases 2 different ways
Two new studies point to the efficient use of gene therapy to treat deadly childhood genetic diseases. The first study used direct gene therapy infusion to treat a rare neurodevelopmental disorder, while the second study used prenatal base editing in mouse models as proof of concept for the treatment of genetic diseases. These vastly different approaches show the promise of gene therapy for a variety of devastating diseases. Read More
Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter